JP2008510015A5 - - Google Patents

Download PDF

Info

Publication number
JP2008510015A5
JP2008510015A5 JP2007527922A JP2007527922A JP2008510015A5 JP 2008510015 A5 JP2008510015 A5 JP 2008510015A5 JP 2007527922 A JP2007527922 A JP 2007527922A JP 2007527922 A JP2007527922 A JP 2007527922A JP 2008510015 A5 JP2008510015 A5 JP 2008510015A5
Authority
JP
Japan
Prior art keywords
ylene
phen
alkyl
nhc
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007527922A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008510015A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/029024 external-priority patent/WO2006023460A2/en
Publication of JP2008510015A publication Critical patent/JP2008510015A/ja
Publication of JP2008510015A5 publication Critical patent/JP2008510015A5/ja
Pending legal-status Critical Current

Links

JP2007527922A 2004-08-16 2005-08-15 β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物 Pending JP2008510015A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60177904P 2004-08-16 2004-08-16
PCT/US2005/029024 WO2006023460A2 (en) 2004-08-16 2005-08-15 COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY

Publications (2)

Publication Number Publication Date
JP2008510015A JP2008510015A (ja) 2008-04-03
JP2008510015A5 true JP2008510015A5 (https=) 2008-09-18

Family

ID=35686492

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007527922A Pending JP2008510015A (ja) 2004-08-16 2005-08-15 β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物

Country Status (4)

Country Link
US (2) US7569586B2 (https=)
EP (1) EP1833822A2 (https=)
JP (1) JP2008510015A (https=)
WO (1) WO2006023460A2 (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
PE20050130A1 (es) * 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP2008510014A (ja) * 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
GB0426164D0 (en) * 2004-11-29 2004-12-29 Novartis Ag Organic compounds
US8429052B2 (en) * 2005-07-19 2013-04-23 Lincoln National Life Insurance Company Method and system for providing employer-sponsored retirement plan
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
BRPI0614290A2 (pt) 2005-08-08 2011-03-22 Argenta Discovery Ltd derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
JP2009523460A (ja) * 2006-01-24 2009-06-25 ドマンティス リミテッド Ｉｌ−４および／またはｉｌ−１３に結合するリガンド
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
TW200745084A (en) * 2006-03-08 2007-12-16 Astrazeneca Ab Novel compounds
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
GB0613154D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
WO2008096129A1 (en) * 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
HRP20120968T1 (hr) * 2008-02-06 2013-01-31 Astrazeneca Ab Spojevi
WO2009154557A1 (en) 2008-06-18 2009-12-23 Astrazeneca Ab Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders
US8263623B2 (en) * 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
WO2010015792A1 (en) * 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
SG175023A1 (en) * 2009-04-14 2011-11-28 Glaxo Group Ltd Process for the preparation of a biphenyl-2-ylcarbamic acid ester
SG175330A1 (en) 2009-04-23 2011-11-28 Theravance Inc DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND ß2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
WO2011048409A1 (en) 2009-10-20 2011-04-28 Astrazeneca Ab Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
US8367829B2 (en) 2010-05-10 2013-02-05 Gilead Sciences, Inc. Bi-functional pyrazolopyridine compounds
EP2569285A1 (en) 2010-05-10 2013-03-20 Gilead Sciences, Inc. Bifunctional quinoline derivatives
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
AR083115A1 (es) * 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
CN103547575B (zh) 2011-06-10 2016-08-17 奇斯药制品公司 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物
HRP20151317T1 (hr) 2011-06-10 2016-01-01 Chiesi Farmaceutici S.P.A. Spojevi koji pokazuju aktivnost prema antagonistima muskarinskog receptora i beta2 adrenergiäśnog receptora
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
WO2014086927A1 (en) 2012-12-06 2014-06-12 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
NZ708738A (en) 2012-12-06 2019-02-22 Chiesi Farm Spa Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
ES2750523T3 (es) 2012-12-18 2020-03-26 Almirall Sa Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3
US9320724B2 (en) 2013-02-13 2016-04-26 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
US9889087B2 (en) 2014-06-10 2018-02-13 The Board Of Trustees Of The Leland Stanford Junior University Intranasal delivery of β2-adrenergic receptor agonists for improving cognition in humans with down syndrome and compositions therefor
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
AR104828A1 (es) 2015-06-01 2017-08-16 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
WO2017093208A1 (en) 2015-12-03 2017-06-08 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN107849035B (zh) * 2015-12-29 2021-12-10 四川海思科制药有限公司 一种苯基杂环衍生物及其在医药上的用途
WO2018011090A1 (en) * 2016-07-13 2018-01-18 Chiesi Farmaceutici S.P.A. Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6485964A (en) 1987-03-12 1989-03-30 Glaxo Group Ltd Compound
CH686869A5 (de) * 1991-04-05 1996-07-31 Sepracor Inc Beta (2) -bronchienerweiternde Arzneistoffe in Form ihrer Bronchienerweiternden Enantiomeren zur Verwendung fuer die Herstellung eines Mittels zur verbesserten Therapie.
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
CZ236894A3 (en) 1992-03-31 1995-09-13 Glaxo Group Ltd Substituted phenylcarbonates and phenylureas, their use for the preparation of pharmaceutical preparations, pharmaceuticals containing thereof and process for preparing such compounds
WO1995021820A1 (en) 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
DE19732607A1 (de) 1997-07-29 1999-02-04 Schneidawind Melitta Nachbrenner für ein Heizungsgerät
JP2002506856A (ja) 1998-03-14 2002-03-05 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング フタラジノンｐｄｅｉｉｉ／ｉｖ阻害剤
ID27887A (id) 1998-04-18 2001-05-03 Glaxo Group Ltd Formulasi aerosol farmasi
GB9808802D0 (en) 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6713651B1 (en) * 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
SE9804000D0 (sv) 1998-11-23 1998-11-23 Astra Ab New composition of matter
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
PT1169019E (pt) 1999-04-14 2003-07-31 Glaxo Group Ltd Formulacao farmaceutica em aerossol
US6593497B1 (en) * 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
AU783095B2 (en) * 1999-12-07 2005-09-22 Theravance Biopharma R&D Ip, Llc Carbamate derivatives having muscarinic receptor antagonist activity
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
EP1366025B1 (en) 2001-03-08 2007-06-27 Glaxo Group Limited Agonists of beta-adrenoreceptors
JP4143413B2 (ja) * 2001-03-22 2008-09-03 グラクソ グループ リミテッド β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体
ES2438985T3 (es) 2001-09-14 2014-01-21 Glaxo Group Limited Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias
US6653323B2 (en) * 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
EP1507754A1 (en) * 2002-05-28 2005-02-23 Theravance, Inc. Alkoxy aryl beta-2 adrenergic receptor agonists
AR040779A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
US7345060B2 (en) * 2003-11-21 2008-03-18 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7320990B2 (en) * 2004-02-13 2008-01-22 Theravance, Inc. Crystalline form of a biphenyl compound

Similar Documents

Publication Publication Date Title
JP2008510015A5 (https=)
JP2008510014A5 (https=)
JP2007501862A5 (https=)
RU2005128557A (ru) Производные бифенила
JP2007514662A5 (https=)
CN100560584C (zh) 具有vr1拮抗剂活性的苯并唑类哌嗪衍生物
JP2006522134A5 (https=)
US20170266199A1 (en) Heterocyclic amides as rip1 kinase inhibitors as medicaments
JP5932848B2 (ja) アモルファス（５−フルオロ−２−メチル−３−キノリン−２−イルメチル−インドール−１−イル）−酢酸
RU2020112759A (ru) Гетероциклические соединения в качестве ингибиторов PAD
CN109790135B (zh) 用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法
CN105218523B (zh) 吡啶衍生物pim激酶抑制剂及其制备方法与在制药中的应用
JP2019142957A (ja) 重水素化２，４−チアゾリジンジオン及び治療方法
JP2015535252A5 (https=)
RU2013154117A (ru) Производные 1-фенил-2-пиридинилалкильных спиртов в качестве ингибиторов фосфодиэстеразы
HRP20161116T1 (hr) NOVI DERIVATI CIKLOHEKSILAMINA KOJI DJELUJU KAO AGONISTI β2 ADRENERGIČKOG RECEPTORA I ANTAGONISTI MUSKARINSKOG ACETILKOLINSKOG RECEPTORA M3
JP2009537461A5 (https=)
CN105130959B (zh) 嘧啶衍生物pim激酶抑制剂及其制备方法与在制药中的应用
CA2722706A1 (en) Di-t-butylphenyl piperazines as calcium channel blockers
CN105254624B (zh) 异噻唑衍生物pim激酶抑制剂及其制备方法与在制药中的应用
EP3303325A1 (en) Cannabinoid receptor mediating compounds
JP2012504603A (ja) 炎症および免疫関連の使用のための化合物
KR101737388B1 (ko) 치매 치료용 ５－ｈｔ４ 수용체 작용제
JP2014521620A5 (https=)
JP2013532146A5 (https=)